



Published in final edited form as:

Nat Genet. 2012 December ; 44(12): 1310–1315. doi:10.1038/ng.2455.

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

Matthieu Le Gallo^{1,*}, Andrea J. O'Hara^{1,*}, Meghan L. Rudd¹, Mary Ellen Urick¹, Nancy F. Hansen², Nigel J. O'Neil³, Jessica C. Price¹, Suiyuan Zhang², Bryant M. England¹, Andrew K. Godwin⁴, Dennis C. Sgroi⁵, NISC Comparative Sequencing Program⁶, Philip Hieter³, James C. Mullikin^{2,6}, Maria J. Merino⁷, and Daphne W. Bell¹

¹Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA

²Genome Technology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA

³Michael Smith Laboratories, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada

⁴Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66106, USA

⁵Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA

⁶NIH Intramural Sequencing Center (NISC), National Institutes of Health, Bethesda, MD 20892, USA

⁷National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Abstract

Endometrial cancer is the 6th most commonly diagnosed cancer among women worldwide, causing ~74,000 deaths annually¹. Serous endometrial cancers are a clinically aggressive subtype

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence to: Dr. Daphne W. Bell, National Human Genome Research Institute, Cancer Genetics Branch, 50 South Drive, MSC-8000, Bethesda, MD 20892; Phone (301) 594-9256; Fax (301) 594-1360; belldaph@mail.nih.gov.

*Denotes equal contribution

Author Contributions

D.W.B. designed and directed the study, and wrote the manuscript. A.K.G. contributed clinical specimens. M.J.M. and D.C.S. conducted pathological review of clinical specimens. M.L.R. prepared DNA samples, performed identity testing and microsatellite instability analysis. NISC performed library construction and whole exome sequencing. NISC and N.F.H. performed variant calling. M.L.G. and A.O.H. curated and orthogonally validated exome sequencing data. M.L.G., A.O.H. and D.W.B. interpreted the exome data and established filtering criteria. M.L.G., A.O.H., M.L.R., J.C.P., B.M.E., S.Z. and D.W.B. designed, performed, analyzed, and interpreted the mutation prevalence screens. A.O.H. and M.L.G. analyzed *MSH6*. M.E.U. and M.L.G. generated sequence conservation alignments. M.E.U. performed cell culture and immunoblotting. N.F.H. M.L.G. and J.C.M. performed statistical analyses. N.F.H. performed the power calculation. D.W.B., M.E.U., M.L.G., M.L.R., A.O.H., N.F.H., J.C.M., A.K.G., P.H. and N.O'N. edited and commented on the manuscript.

Competing Financial Interests

The authors declare no competing financial interests.

with a poorly defined genetic etiology²⁻⁴. We used whole exome sequencing (WES) to comprehensively search for somatic mutations within ~22,000 protein-encoding genes among 13 primary serous endometrial tumors. We subsequently resequenced 18 genes that were mutated in more than one tumor, and/or were genes that formed an enriched functional grouping, from 40 additional serous tumors. We identified high frequencies of somatic mutations in *CHD4* (17%), *EP300* (8%), *ARID1A* (6%), *TSPYL2* (6%), *FBXW7* (29%), *SPOP* (8%), *MAP3K4* (6%) and *ABCC9* (6%). Overall, 36.5% of serous tumors had mutated a chromatin-remodeling gene and 35% had mutated a ubiquitin ligase complex gene, implicating the frequent mutational disruption of these processes in the molecular pathogenesis of one of the deadliest forms of endometrial cancer.

We performed targeted exon capture and next generation sequencing on DNA from 13 primary serous endometrial tumors with high neoplastic cellularity (Supplementary Table 1) and matched normal DNA. The mean depth of coverage for aligned reads was 102.6× and on average 89.5% of targeted bases had sufficient coverage and quality for variant calling (Supplementary Table 2). Using stringent filtering criteria, which included an empirically determined threshold that accounted for read quality and depth and provided an optimal balance between positive predictive value (86.1%) and sensitivity (97.3%) (Materials and Methods), we identified 1,522 exonic somatic mutations (1,183 nonsynonymous: 339 synonymous) and 22 splice junction mutations within the protein-encoding genes of the 13 tumors (Supplementary Figure 1). One tumor had an apparent hypermutable phenotype with a greater number of mutations and a different mutation signature than the other 12 tumors (Supplementary Figure 2; Supplementary Table 3 and Supplementary Table 4) and was excluded from subsequent analyses.

Among the remaining 12 tumors we identified 516 exonic mutations (380 nonsynonymous and 136 synonymous) and 11 splice junction mutations (Supplementary Table 5). We could orthogonally assess 510 of the 527 exonic/splice junction mutations by Sanger sequencing; 86.1% (439 of 510) of mutations confirmed as somatic (Supplementary Table 5 and Supplementary Table 6). The validated somatic mutations included 321 nonsynonymous mutations (279 missense, 86.9%; 19 nonsense, 5.9%; 17 frameshift, 5.3%; 6 in-frame insertions/deletions, 1.9%) and 9 splice junction mutations among 304 protein-encoding genes, and 109 synonymous mutations (Supplementary Table 5). There was a mean of 27.5 validated nonsynonymous and splice junction mutations per tumor (range 5-55) (Supplementary Table 6). The predicted functional impact of the validated missense mutations was assessed *in silico*; 34.4% of 241 missense mutations that could be assessed by both the SIFT and Mutation Assessor algorithms are predicted to impact protein function (Supplementary Table 5).

To prioritize our search for novel driver mutations in serous endometrial cancer, we focused on the nine genes that had validated nonsynonymous somatic mutations in more than one tumor (Supplementary Table 7). We resequenced these genes in a prevalence screen of 40 additional serous endometrial tumors. Three of the nine genes (*TP53*, *PIK3CA*, and *PPP2RIA*) have established roles in the pathogenesis of serous endometrial cancer⁵⁻⁸. Among the 52 serous tumors in our study, *TP53*, *PIK3CA*, and *PPP2RIA* were mutated,

respectively, in 71%, 31%, and 25% of tumors, as reported here and in a previous study from our group⁶ (Supplementary Table 8 and Supplementary Table 9). The other six genes (*CHD4*, *SPOP*, *FBXW7*, *ABCC9*, *CYP4X1*, *MAP3K4*) have no previously reported role in serous endometrial cancer. The combined discovery and prevalence screens revealed high frequency somatic mutations in *CHD4* (17%), *FBXW7* (29%), *SPOP* (8%), *MAP3K4* (6%), *ABCC9* (6%), and *CYP4X1* (4%) (Table 1, Figure 1, Supplementary Table 9, Supplementary Figure 3, and Supplementary Figure 4). The mutation rates for *CHD4*, *FBXW7*, and *SPOP* were significantly higher than the background mutation rate ($q = 0.0353$) (Supplementary Table 10).

In addition to serous tumors, the major histological subtypes of endometrial cancer are clear cell and endometrioid, with overall 5-year relative survival rates of 45%, 65% and 91%, respectively⁹. For comparison across subtypes, we resequenced *CHD4*, *FBXW7*, and *SPOP* from 23 clear cell, 67 endometrioid, and 18 mixed histology endometrial tumors. Collectively, these three genes were somatically mutated in 40% of serous, 26% of clear cell, 15% of endometrioid, and 17% of mixed histology endometrial cancers (Supplementary Table 9). There was no significant association between mutations in *CHD4*, *FBXW7* or *SPOP* and microsatellite instability or *MSH6* mutations (Supplementary Table 11, Supplementary Table 12, Supplementary Figure 5).

CHD4 (Chromodomain-helicase-DNA-binding protein 4) is a catalytic subunit of the NuRD complex, which regulates transcriptional repression, chromatin assembly, and the DNA damage response¹⁰⁻¹⁹. We confirmed endogenous *CHD4* expression in endometrial cancer cells (Supplementary Figure 6). *CHD4* was highly mutated in serous tumors (17%), and was also mutated in clear cell (4%), endometrioid (7%), and mixed histology (11%) tumors (Supplementary Table 9). Eighty-percent of *CHD4* missense mutations, including an arginine-1162 (*CHD4*^{Arg1162}) hotspot, are predicted to impact protein function (Table 1, **and** Figure 1). Most *CHD4* mutations were missense mutations; 83% of all *CHD4* mutations affected residues that are highly conserved throughout evolution or across closely related family members (Supplementary Figure 7 and Supplementary Figure 8).

Half of all *CHD4* mutations localized to the ATPase/helicase domains (Figure 1a); two-thirds (6 of 9) of those mutations localized to conserved residues that undergo germline or *de novo* pathogenic mutations in *SMARCAL1*, *SMARCA4*, or *SMARCA2* causing Schimke immune-osseous dysplasia, Coffin-Siris syndrome, and Nicolaides-Baraitser syndrome (Supplementary Figure 9)²⁰⁻²². This observation leads us to speculate that somatic mutations in the ATPase/helicase domain of *CHD4* may be driver mutations in endometrial cancer.

Other frequently mutated genes in our study were *FBXW7* and *SPOP*. The *FBXW7* (F-box and WD repeat domain containing 7) tumor suppressor is a component of the *FBXW7*-*SKP1*-*CUL1* ubiquitin ligase complex, which mediates ubiquitination and proteasomal degradation of phosphoprotein substrates including *CYCLIN-E*, *NOTCH*, *JUN*, and *C-MYC*²³. Previous reports of *FBXW7* mutations in endometrial cancer either did not include serous and clear cell tumors or did not report the histology of mutated cases²⁴⁻²⁷. We identified *FBXW7* mutations in 29% of serous, 13% of clear cell, 10% of endometrioid, and

11% of mixed histology endometrial cancers (Supplementary Table 9). The mutation frequency was significantly higher among serous tumors than high-grade endometrioid tumors (29% versus 0%, $P=0.0146$ Fisher's 2-tailed Exact test of significance). Most *FBXW7* mutations localized to the substrate binding WD-repeats (Figure 1b), consistent with the mutation spectrum in other cancers²⁸. Forty-six percent of *FBXW7* missense mutations in our study are known loss-of-function mutations; another 39% of missense mutations are predicted to affect function²⁹ (Table 1). Our findings may be clinically relevant since loss of *FBXW7* function correlates with resistance to antitubulin chemotherapeutics³⁰ and sensitivity to an HDAC inhibitor³¹.

SPOP (*Speckle-type POZ Protein*) was somatically mutated in serous (8%) and clear cell tumors (9%) but was not mutated in endometrioid or mixed histology tumors (Supplementary Table 9). The mutation frequency was statistically significantly higher in serous than in endometrioid tumors (8% versus 0%, $P=0.0341$, Fisher's 2-tailed Exact test of significance). *SPOP* forms part of a multi-subunit CULLIN3 (*CUL3*)-dependent ubiquitin ligase complex, and has recently been shown to be mutated at high frequency in prostate cancer³². All *SPOP* mutations in endometrial cancer, including a recurrent *SPOP*^{Ser80Arg} mutant, localized to highly evolutionarily conserved residues within the MATH domain that acts as the substrate recognition domain to bind proteins targeted for ubiquitin-mediated degradation (Figure 1c). This localization is strikingly similar to the localization of loss-of-function mutations to the substrate recognition domain of *FBXW7* (Figure 1b). Thus, we predict that *SPOP* mutations in endometrial cancer are likely to be loss-of-function mutants with impaired substrate binding. Intriguingly, the SRC-3/AIB1 oncoprotein, an *SPOP* substrate³³, is overexpressed in endometrial cancer independent of gene amplification³⁴.

To identify additional candidate driver genes for serous endometrial cancer, we evaluated the functional relationships of the 304 protein-encoding genes that had orthogonally validated mutations (nonsynonymous or splice junction) in the discovery screen (Supplementary Table 13 and Supplementary Table 14)^{35,36}. One of the enriched functional groupings was chromatin modification, which was formed by *CHD4* and ten other genes (*EP300*, *ARID1A*, *TSPYL2*, *KDM4B*, *TRIM16*, *HDAC7*, *CTCF*, *YEATS4*, *TRRAP*, and *BAZ1B*) (Supplementary Table 13). Although this enriched grouping did not achieve statistical significance following multiple testing correction, we focused on it because it contained *CHD4*, one of the most highly mutated genes identified in our study, and because chromatin-remodeling genes are a frequent target of somatic mutations in other types of cancer³⁷⁻⁵⁰. We therefore resequenced the ten additional chromatin-remodeling genes from 40 additional serous and 23 clear cell endometrial tumors. In the combined discovery and prevalence screens, the 11 chromatin-remodeling genes were somatically mutated in 36.5% of serous tumors and 22% of clear cell tumors (Table 1, Table 2, and Figure 2). Two of the mutated genes, *EP300* (*E1A binding protein p300*) and *ARID1A* (*AT rich interactive domain 1A*, *SWI-like*), are consensus cancer genes. *EP300* and *ARID1A* were mutated, respectively, in 8% and 6% of serous tumors and in 4% and 13% of clear cell tumors (Table 2). Most *EP300* mutations localized within the histone acetyltransferase domain of p300, a global transcriptional co-activator (Figure 3a). p300^{Arg1627} formed a mutation hotspot in EC; the p300^{Arg1627Trp} mutation has also been described in lymphoma⁵¹. *ARID1A* encodes the

BAF250A tumor suppressor, a subunit of the SWI/SNF-A chromatin-remodeling complex^{43,49,52-54}. Most *ARID1A* mutations we uncovered are predicted to truncate BAF250A (Figure 3b), consistent with the mutation spectrum in other tumors^{43,49,55}. Our finding of *ARID1A* mutations in 6% of serous endometrial cancers is consistent with a recent study by McConechy et al., which documented *ARID1A* mutations in 11% of serous endometrial tumors⁵⁶. To our knowledge, this is the first report of *ARID1A* mutations in clear cell endometrial cancer, substantiating previous reports of loss of BAF250A expression in this histotype⁵⁷.

Our study provides novel insights into the somatic mutations present in serous endometrial cancer exomes. However, it is important to acknowledge that our discovery screen is underpowered to detect all somatically mutated genes that drive serous tumors. For example, *PIK3R1*, which we previously found to be somatically mutated in 8% of serous endometrial tumors⁵⁸, was not somatically mutated among the tumors that formed our discovery screen. We estimate that for genes that are mutated in 8% of all serous endometrial cancers, a discovery screen of 12 tumors has 25% power to detect two mutated tumors and 63% power to detect one mutated tumor (Supplementary Table 15); for genes that are mutated in 20% of all serous endometrial cancers, our discovery screen has an estimated 72.5% power to detect two mutated tumors and 93% power to detect one mutated tumor. Massively parallel sequencing of additional cases will undoubtedly yield deeper insights into the mutational landscape of serous endometrial cancer.

Herein we report the first exome sequence analysis of serous endometrial cancers, which are clinically aggressive tumors that have been poorly characterized genomically. Our findings implicate the disruption of chromatin-remodeling and ubiquitin ligase complex genes in 50% of serous endometrial tumors and 35% of clear cell endometrial tumors (Figure 2). The high frequency and specific distribution of mutations in *CHD4*, *FBXW7*, and *SPOP* strongly suggests these are likely to be driver events in serous endometrial cancer.

Methods

Clinical material

Anonymized, snap-frozen primary tumor tissues, corresponding hematoxylin and eosin-stained tumor sections, matched normal tissues (uninvolved reproductive tissue or whole blood), and clinicopathological information were obtained from the Cooperative Human Tissue Network, which is funded by the National Cancer Institute. The NIH Office of Human Subjects Research determined that this research was not “human subjects research” per the Common Rule (45 CFR 46), and therefore that no IRB review was required for whole exome sequencing of these samples. A small number of samples in the prevalence screen were obtained from the Biosample Repository at Fox Chase Cancer Center, or from Oncomatrix, Inc (San Marcos, CA). Tumor specimens were collected at surgical resection, before treatment. Histological classifications were based upon the entire specimen at time of diagnosis. Tumors consisted of 53 serous cases, 23 clear cell cases, 67 endometrioid cases and 18 cases of mixed histology. A pathologist reviewed hematoxylin and eosin-stained sections of banked tumor tissues, to verify that they were representative of the original

histological classification, and to delineate regions of high tumor cell content (>70%) for macrodissection.

DNA extraction and identity testing

Genomic DNA was isolated from macrodissected tumor tissues and normal tissues using the PUREGENE kit (Qiagen), followed by phenol-chloroform purification. Tumor-normal pairs were typed using the Coriell Identity Mapping kit (Coriell). Genotyping fragments were resolved on an ABI-3730xl DNA analyzer (Applied Biosystems) and scored using GeneMapper software.

Exome capture, library construction, and next generation sequencing

Exomes of tumor-normal pairs were captured using the Agilent SureSelect Human All Exon Kit (3 pairs) or the Agilent SureSelect Human All Exon 50 Mb Target Enrichment kit (10 pairs) according to the manufacturer's instructions. DNAs captured using the SureSelect Human All Exon Kit were run on an Illumina GAIIx platform with version 4 chemistry and version 2 flowcells; DNAs captured using the SureSelect Human All Exon 50 Mb Target Enrichment kit were run on an Illumina GAIIx platform with version 5 chemistry and version 4 flowcells, according to the manufacturer's instructions to generate 75- or 100-base paired end reads.

Read mapping and genotype calling

Next generation sequence reads were initially mapped to the human reference sequence NCBI build 36 (hg18) using the Illumina ELAND alignment algorithm. When at least one read in a pair mapped to a unique location in the genome, that read and its pair were subjected to a more accurate gapped alignment to the 100kb region surrounding the location with cross_match (URL: <http://www.phrap.org/phredphrapconsed.html>). Alignments were stored in BAM format, and fed as input to bam2mpg (URL: <http://research.nhgri.nih.gov/software/bam2mpg/>), to call genotypes at all covered positions using a probabilistic Bayesian algorithm referred to as the most-probable-genotype (MPG) algorithm⁵⁹. Highly reliable genotypes have an MPG score $> 10^{-59}$. For tumor samples, bam2mpg was run with the --score_variant option, in order to calculate a "most probable variant" (MPV) score, which assesses the posterior probability of the existence of any variant at a position, and therefore is more sensitive than the MPG score at positions for which there is uncertainty about whether a variant is heterozygous or homozygous non-reference. Additional information on the MPG and MPV scores is provided in the Supplementary Note.

Filtering of variant calls

We used a number of steps to filter nucleotide variants identified in the whole exome screen. Germline variants called in paired tumor-normal samples were excluded from further analysis. Variants that were present within dbSNP build 132, but which were not annotated as pathogenic or probable pathogenic variants within dbSNP, were also excluded. We compared the remaining variants in each tumor exome to the variants in all 13 normal exomes sequenced in this study; variants called in both a tumor exome and a normal exome were excluded. Variants representing probable mapping ambiguities were also excluded. All

remaining variants were considered to be potential somatic mutations and were annotated using the VarSifter software package⁶⁰ into bins representing mutations in exons, introns, splice junctions, UTRs, and non-coding RNAs.

Establishment of filtering criteria based on read score and read depth

After filtering the exome data to exclude germline variants and probable mapping ambiguities, 798 somatic variants were called in the exons and splice junctions of 12 tumors (Supplementary Figure 1 and Supplementary Table 16). We were able to orthogonally assess 730 of the 798 variants by Sanger sequencing; PCR products could not be generated for the remaining 68 variants. Of the 730 variants tested by Sanger sequencing, 451 variants orthogonally validated as somatic (present in tumor and absent from matched normal DNA) yielding a positive predictive value of 61.8% (451 of 730). The remaining variants were either not detected within the tumor or were germline (present in both tumor and matched normal DNA).

Because a positive predictive value of 61.8% was unacceptably low, we sought to empirically establish filtering criteria, based on sequence quality (MPV/MPG score) and read depth (coverage), to achieve an optimal balance between accuracy and sensitivity of mutation detection. We observed (Supplementary Figure 10) that the majority of mutations that did not orthogonally validate as somatic by Sanger sequencing had (i) < 5 reads in the tumor or normal samples; (ii) an MPG score < 10 in the normal sample and/or an MPV score < 10 in the tumor sample, (iii) an MPG:COV ratio of < 0.5 in the normal sample.

We therefore retrospectively imposed filtering criteria of (i) at least 5 reads in the tumor and normal samples and (ii) an MPG score of ≥ 10 in the normal sample and an MPV score of ≥ 10 in the tumor sample; and (iii) an MPG:COV ratio ≥ 0.5 in the normal sample, to the 798 somatic variants called by exome sequencing; 527 variants were retained after filtering (Supplementary Table 5). Filtering on score and read depth attained a positive predictive value of 86.1% (510 of 527 retained variants could be assessed by Sanger sequencing; 439 of 510 (86.1%) assessed variants orthogonally validated as somatic mutations) and a sensitivity of 97.3% (439 of 451 orthogonally validated mutations observed before applying the coverage-score filter were retained after filtering).

Filtering criteria of (i) at least 5 reads in the tumor sample and normal sample and (ii) an MPV score of ≥ 10 in the tumor sample and an MPG score of ≥ 10 in the normal sample; (iii) an MPG:COV ratio ≥ 0.5 in the normal sample, was also applied to the 1,042 somatic variants called in T155 by exome sequencing (Supplementary Table 17); 1,017 variants were retained after filtering (Supplementary Table 4).

Predicting the functional significance of missense mutations

Nonsynonymous missense mutations called by whole exome sequencing were evaluated *in silico* using the SIFT (<http://sift.jcvi.org/>) and Mutation Assessor (<http://mutationassessor.org/>) algorithms to predict their impact on protein function. A SIFT prediction of “deleterious” and a Mutation Assessor predictions of “medium impact” or “high impact” were considered to predict an impact on protein function.

Power of study design

Assuming N tumor samples are sequenced in a discovery screen, and a fraction X of all tumor samples have gene G mutated, the probability that the N samples sequenced contain 0 samples with the gene mutation is $(1-X)^N$. Therefore, the probability of observing gene G mutated at least once in the discovery screen is $1 - (1-X)^N$, which is 93% for 12 discovery samples, assuming $X = 0.20$, or 20%. Likewise, the probability of observing 0 or 1 samples with a mutation in gene G is $(1-X)^N + N(1-X)^{(N-1)}X$, giving the probability of seeing the mutation twice or more as $1 - (1-X)^N - N(1-X)^{(N-1)}X$, which is 73% for 12 tumors, assuming $X=0.20$.

PCR amplification and Sanger sequencing

Genomic DNA (5ng) was amplified using M13-tailed primers (Supplementary Table 18) in a 10 μ l polymerase chain reaction (PCR) containing 1X AmpliTaq Gold PCR buffer (Applied Biosystems), 1.5mM MgCl₂, 75mM dNTP, 400nM sense primer, 400nM antisense primer, and 0.5 units of AmpliTaq Gold DNA polymerase. PCR amplification was performed on a GeneAmp® PCR System 9700 (Applied Biosystems). PCR amplicons were purified using exonuclease I (Epicentre Biotechnologies) and shrimp alkaline phosphatase (USB Corporation) and bidirectionally sequenced using the Big Dye Terminator v.3.1 kit (Applied Biosystems) and M13 primers. Cycle sequencing products were run on an ABI-3730xl DNA analyzer (Applied Biosystems). Tumor and reference sequences were aligned, and compared using in-house software to determine the genotype of variant nucleotide positions. Non-pathogenic variants present in dbSNP were excluded from further analysis. True somatic mutations were confirmed by reamplification and sequencing of matched tumor-normal DNAs and analyzed using Sequencher software (Gene Codes Corporation).

Determination of mutation rates and statistical analyses

The somatic mutation rate was determined by dividing the total number of exonic mutations present within a tumor (after filtering on quality score and coverage) by the number of the exonic bases that had adequate quality and coverage in both the tumor sample (MPV score 10 and at least 5 reads) and paired normal sample (MPG score 10, MPG:COV ratio 0.5, and at least 5 reads). A Grubb's test was used to calculate an approximate p-value for each tumor to identify outliers. A uniform background mutation rate equal to the rate observed in the discovery phase was assumed, and a Poisson distribution function was used to calculate p-values for the observed number of mutations in each gene. False discovery rates were calculated using the Benjamini Hochberg method⁶¹, correcting for 21,441 genes tested. This method is a simplified version of the CaMP (cancer mutation prevalence) scoring method⁶² including subsequently suggested corrections⁶³.

Functional enrichment analyses *in silico*

The 304 somatically mutated protein-encoding genes identified and orthogonally validated in the discovery screen were analyzed for enriched functional groupings using the Database for Annotation Visualization and Integrated Discovery (DAVID)^{35,36}, and Ingenuity

Systems Pathway Analysis (IPA) *in silico* tools (www.ingenuity.com). The Bonferroni, Benjamini, and FDR values, computed within DAVID, were assessed for significance.

Determination of defective mismatch repair

Tumor-normal DNA pairs were screened for the presence of microsatellite instability (MSI) using the Promega Microsatellite Instability Analysis System v1.2 (Promega) according to the manufacturer's instructions. All coding exons of *MSH6* were PCR amplified and Sanger sequenced.

Cell lines

Endometrial cancer cell lines (RL-95-2, HEC1A, HEC1B, KLE, ANC3A) were obtained from the American Type Culture Collection, or the NCI Developmental Therapeutics Program cell line repository. ARK1 and ARK2 serous endometrial cancer cell lines were kindly provided by Dr. Alessandro Santin (Yale School of Medicine).

Immunoblotting

Cells were lysed in RIPA buffer (Thermo Scientific) containing 1mM Naorthovanadate, 10mM NaF, and 1X protease inhibitor cocktail (Roche). Lysates were centrifuged followed by denaturing at 95°C in 2X SDS sample buffer (Sigma) prior to SDS-PAGE and transfer to PVDF membranes (Bio-Rad). Primary and HRP-conjugated secondary antibodies were: CHD4 (Cell Signaling), β -Actin (Sigma), goat anti-mouse HRP (Cell Signaling), and goat anti-rabbit HRP (Cell Signaling). Immunoreactive proteins were visualized with enhanced chemiluminescence (Pierce).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank our colleagues for critical reading of the manuscript; R. Travis Moreland and Niraj Trivedi of the NHGRI Bioinformatics and Scientific Programming Core for, respectively, performing *in silico* PCR and advice on statistics; and Dr. Jamie Teer for sharing expertise on VarSifter. Dr. Alessandro Santin kindly provided the ARK1 and ARK2 cell lines. Funded in part by the Intramural Program of the National Human Genome Research Institute, National Institutes of Health (DWB and JCM); NIH grant R01CA112021 (DCS); the Avon Foundation (DCS); NIH grant R01CA140323 (AKG); the Ovarian Cancer Fund (AKG); PH is supported by grants from the NIH grant (CA016519) and by the Canadian Institutes for Health Research (MOP-38096).

References

1. Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010; 127:2893–917. [PubMed: 21351269]
2. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. *Mod Pathol*. 2000; 13:295–308. [PubMed: 10757340]
3. Hamilton CA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. *Br J Cancer*. 2006; 94:642–6. [PubMed: 16495918]
4. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. *Am J Surg Pathol*. 1982; 6:93–108. [PubMed: 7102898]

5. McConechy MK, et al. Subtype-specific mutation of *PPP2R1A* in endometrial and ovarian carcinomas. *J Pathol.* 2011; 223:567–73. [PubMed: 21381030]
6. Rudd ML, et al. A unique spectrum of somatic *PIK3CA* (p110 α) mutations within primary endometrial carcinomas. *Clin Cancer Res.* 2011; 17:1331–40. [PubMed: 21266528]
7. Shih Ie M, et al. Somatic mutations of *PPP2R1A* in ovarian and uterine carcinomas. *Am J Pathol.* 2011; 178:1442–7. [PubMed: 21435433]
8. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of *EGFR* and *PIK3CA* in uterine serous carcinoma. *Gynecol Oncol.* 2009; 113:370–3. [PubMed: 19272638]
9. Ries, LAG., et al. Patient and tumor characteristics. National Cancer Institute, SEER Program; Bethesda, MD: 2007. SEER Survival Monograph: Cancer survival among adults: U.S. SEER Program, 1988-2001. NIH Pub. No. 07-62152007
10. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. *Cell.* 1998; 95:279–89. [PubMed: 9790534]
11. Li J, Lin Q, Wang W, Wade P, Wong J. Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. *Genes Dev.* 2002; 16:687–92. [PubMed: 11914274]
12. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. *Nature.* 1998; 395:917–21. [PubMed: 9804427]
13. Xue Y, et al. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. *Mol Cell.* 1998; 2:851–61. [PubMed: 9885572]
14. Hall JA, Georgel PT. CHD proteins: a diverse family with strong ties. *BCB.* 2007; 85:463–76.
15. Lai AY, Wade PA. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. *Nat Rev Cancer.* 2011; 11:588–96. [PubMed: 21734722]
16. Polo SE, Kaidi A, Baskcomb L, Galanty Y, Jackson SP. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. *EMBO J.* 2010; 29:3130–9. [PubMed: 20693977]
17. Smeenk G, et al. The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage. *J Cell Biol.* 2010; 190:741–9. [PubMed: 20805320]
18. Chou DM, et al. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. *Proc Natl Acad Sci USA.* 2010; 107:18475–80. [PubMed: 20937877]
19. Larsen DH, et al. The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage. *J Cell Biol.* 2010; 190:731–40. [PubMed: 20805324]
20. Boerkoel CF, et al. Mutant chromatin remodeling protein SMARCA1 causes Schimke immunosseous dysplasia. *Nat Genet.* 2002; 30:215–20. [PubMed: 11799392]
21. Tsurusaki Y, et al. Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. *Nat Genet.* 2012; 44:376–8. [PubMed: 22426308]
22. Van Houdt JK, et al. Heterozygous missense mutations in *SMARCA2* cause Nicolaides-Baraitser syndrome. *Nat Genet.* 2012; 44:445–9. [PubMed: 22366787]
23. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. *Nat Rev Cancer.* 2008; 8:83–93. [PubMed: 18094723]
24. Cassia R, et al. Cyclin E gene (*CCNE*) amplification and *hCDC4* mutations in endometrial carcinoma. *J Pathol.* 2003; 201:589–95. [PubMed: 14648662]
25. Dutt A, et al. Drug-sensitive *FGFR2* mutations in endometrial carcinoma. *Proc Natl Acad Sci U S A.* 2008; 105:8713–7. [PubMed: 18552176]
26. Spruck CH, et al. *hCDC4* gene mutations in endometrial cancer. *Cancer Res.* 2002; 62:4535–9. [PubMed: 12183400]
27. Suehiro Y, et al. Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of *CDH13* hypermethylation. *Clin Cancer Res.* 2008; 14:3354–61. [PubMed: 18519763]

28. Forbes SA, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). *Curr Protoc Hum Genet.* 2008 Chapter 10, Unit 10 11.
29. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. *Nucleic Acids Res.* 2011; 39:e118. [PubMed: 21727090]
30. Wertz IE, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. *Nature.* 2011; 471:110–4. [PubMed: 21368834]
31. Garnett MJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature.* 2012; 483:570–5. [PubMed: 22460902]
32. Barbieri CE, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nat Genet.* 2012; 44:685–9. [PubMed: 22610119]
33. Li C, et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. *Oncogene.* 2011; 30:4350–6. [PubMed: 21577200]
34. Glaeser M, Floetotto T, Hanstein B, Beckmann MW, Niederacher D. Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. *Horm Metab Res.* 2001; 33:121–6. [PubMed: 11355743]
35. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc.* 2009; 4:44–57. [PubMed: 19131956]
36. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* 2009; 37:1–13. [PubMed: 19033363]
37. Dalgliesh GL, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature.* 2010; 463:360–3. [PubMed: 20054297]
38. Fujimoto A, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. *Nat Genet.* 2012; 44:760–4. [PubMed: 22634756]
39. Grasso CS, et al. The mutational landscape of lethal castration-resistant prostate cancer. *Nature.* 2012; 487:239–43. [PubMed: 22722839]
40. Gui Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. *Nat Genet.* 2011; 43:875–8. [PubMed: 21822268]
41. Guichard C, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. *Nat Genet.* 2012; 44:694–8. [PubMed: 22561517]
42. Jiao Y, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science.* 2011; 331:1199–203. [PubMed: 21252315]
43. Jones S, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science.* 2010; 330:228–31. [PubMed: 20826764]
44. Ong CK, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. *Nat Genet.* 2012; 44:690–3. [PubMed: 22561520]
45. Parsons DW, et al. The genetic landscape of the childhood cancer medulloblastoma. *Science.* 2011; 331:435–9. [PubMed: 21163964]
46. Schwartzentruber J, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature.* 2012; 482:226–31. [PubMed: 22286061]
47. Shain AH, et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. *Proc Natl Acad Sci USA.* 2012; 109:E252–9. [PubMed: 22233809]
48. Varela I, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature.* 2011; 469:539–42. [PubMed: 21248752]
49. Wiegand KC, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med.* 2010; 363:1532–43. [PubMed: 20942669]
50. Wang K, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. *Nat Genet.* 2011; 43:1219–23. [PubMed: 22037554]
51. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell.* 1996; 87:953–9. [PubMed: 8945521]

52. Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. *Gene Chromosome Canc.* 2007; 46:745–50.
53. Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. *Cancer Res.* 2011; 71:6718–27. [PubMed: 21900401]
54. Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. *Cell Res.* 2011; 21:396–420. [PubMed: 21358755]
55. Guan B, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. *Am J Surg Pathol.* 2011; 35:625–32. [PubMed: 21412130]
56. McConechy MK, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. *J Pathol.* 2012 doi: 10.1002/path.4056.
57. Wiegand KC, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. *J Pathol.* 2011; 224:328–33. [PubMed: 21590771]
58. Urlick ME, et al. PIK3R1 (p85-alpha/p85{alpha}) is somatically mutated at high frequency in primary endometrial cancer. *Can Res.* 2011; 71:4061–7.
59. Teer JK, et al. Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing. *Genome Res.* 2010; 20:1420–31. [PubMed: 20810667]
60. Teer JK, Green ED, Mullikin JC, Biesecker LG. VarSifter: visualizing and analyzing exome-scale sequence variation data on a desktop computer. *Bioinformatics.* 2012; 28:599–600. [PubMed: 22210868]
61. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc.* 1995; 57:289–300.
62. Sjoblom T, et al. The consensus coding sequences of human breast and colorectal cancers. *Science.* 2006; 314:268–74. [PubMed: 16959974]
63. Rubin AF, Green P. Comment on “The consensus coding sequences of human breast and colorectal cancers”. *Science.* 2007; 317:1500. [PubMed: 17872429]




Figure 1. Somatic mutations in *CHD4*, *FBXW7*, and *SPOP* cluster within important functional domains of the encoded proteins

Schematic representation of the *CHD4*, *FBXW7*, and *SPOP* proteins showing the positions of individual somatic mutations identified among primary endometrial tumors relative to important functional domains. Mutations in serous (yellow boxes), clear cell (brown boxes), endometrioid (red boxes) and mixed histology (white boxes) endometrial tumors are indicated. (a) 50% of all *CHD4* mutations localize within the ATPase/helicase and helicase domains (top). (b) The majority of *FBXW7* mutations in endometrial cancer cluster within the WD repeats. The *FBXW7*-Glu65* and -Lys70fs*27 mutations (not displayed) are within an alternate isoform. (c) All *SPOP* mutations in endometrial cancer localized to the MATH domain. BTB domain, Broad-complex, Tramtrack and Bric-a-brac domain; D-domain, Dimerization domain; MATH, Meprin and TRAF Homology; NLS, nuclear localization signal; PHD, Plant Homeo Domain-type zinc fingers; WD repeats, tryptophan-aspartic acid repeats.




Figure 2. Oncoprint showing the distribution of nonsynonymous somatic mutations in ubiquitin ligase complex genes and chromatin-remodeling genes among 26 serous and 8 clear cell endometrial tumors, and in *TP53*, *PPP2R1A*, and *PIK3CA* among 26 serous tumors
 Individual tumors are indicated by blue bars. Nonsynonymous somatic mutations are indicated by yellow bars. Only tumors that had somatically mutated the ubiquitin ligase complex genes and chromatin-remodeling genes are shown. Collectively, the two ubiquitin ligase complex genes that regulate ubiquitin (Ub) mediated proteolysis were mutated in 35% (18 of 52) of serous endometrial tumors and 22% (5 of 23) of clear cell endometrial tumors; the 11 chromatin-remodeling genes were mutated in 36.5% (19 of 52) of serous endometrial tumors and 22% (5 of 23) of clear cell endometrial tumors. (*) The *PIK3CA* mutation pattern was previously reported in Rudd et al ⁶.




Figure 3. Somatic mutations in the consensus cancer genes *EP300*, and *ARID1A*, relative to the functional domains of the encoded proteins

Schematic representation of the (a) p300 and (b) BAF250A proteins, showing the positions of individual somatic mutations identified among primary endometrial tumors. Mutations in serous (yellow boxes) and clear cell (brown boxes) endometrial tumors are distinguished. Known functional domains of each protein are indicated. ARID, AT-rich Interaction Domain; BD, Bromodomain; KIX, KIX domain; PHD, Plant Homeo Domain Finger; TAZ, zinc finger TAZ-type; ZZ, zinc finger ZZ type.

Table 1

Somatic mutations identified in the discovery and prevalence screens of *CHD4*, *FBXW7*, *SPOP*, *MAP3K4*, *ABCC9*, and *CYP4X1*.

Gene Name (RefSeq ID; UCSC Transcript Accession ID ^)	Tumor	Histology	Nucleotide Change	Amino Acid Change	Mutation type	Mutation Assessor Predicted Effect on Function
<i>CHD4</i> (NM_001273; uc001qpo.2)	T3 (OMI323)	Serous	c.2450G>A	p.Arg817Gln	Missense	Medium
	T3 (OMI323)	Serous	c.4709G>A	p.Ser1570Asn	Missense	Low
	T10 (OM2009)	Serous	c.4013G>A	p.Arg1338Lys	Missense	Medium
	T29	Serous	c.3314G>A	p.Arg1105Gln	Missense	High
	T50	Serous	c.3452A>C	p.His1151Arg	Missense	High
	T78	Serous	c.2734T>C	p.Leu912Val	Missense	High
	T165	Serous	c.4001G>T	p.Gly1334Val	Missense	Medium
	T33	Serous	c.3485G>A	p.Arg1162Gln	Missense	High
	T154	Serous	c.1672G>T	p.Val558Phe	Missense	Medium
	T56	Serous	c.3460_3462delATT	p.del1152Asn	In-frame deletion	-
	T59	Clear cell	c.2629C>T	p.Arg877Trp	Missense	High
	T97	Endometrioid	c.1715G>A	p.Arg572Gln	Missense	Medium
	T115	Endometrioid	c.4946C>T	p.Ala1649Val	Missense	Low
	T120	Endometrioid	c.2620_2622delGAA	p.del874Glu	In-frame deletion	-
	T126	Endometrioid	c.5704G>A	p.Glu1902Lys	Missense	Low
	T133	Endometrioid	c.3484C>T	p.Arg1162Trp	Missense	High
	T173	Mixed	c.3644T>C	p.Leu1215Pro	Missense	High
	T179	Mixed	c.218delA	p.Lys72Argfs*128	Frameshift	-
<i>FBXW7</i> (NM_018315; uc003imr.2)	T3 (OMI323)	Serous	c.193G>T	p.Glu65*	Nonsense	-
	T113	Clear cell	c.207_208insA	p.Asn69Lysfs*26	Frameshift	-
(NM_033632; uc003ims.2)	T3 (OMI323)	Serous	c.288A>C	p.Glu96Asp	Missense	Neutral

Gene Name (RefSeq ID; UCSC Transcript Accession ID ^(*))	Tumor	Histology	Nucleotide Change	Amino Acid Change	Mutation type	Mutation Assessor Predicted Effect on Function
	T43	Serous	c.1590_1608delTTGAAACCTCTCTACACACG	p.Glu531Cysfs*19	Frameshift	-
	T50	Serous	c.1436G>A	p.Arg479Gln	Missense	Medium ∇
	T53	Serous	c.1393C>T	p.Arg465Cys	Missense	Medium ∇
	T74	Serous	c.1394G>A	p.Arg465His	Missense	High ∇
	T78	Serous	c.1394G>A	p.Arg465His	Missense	High ∇
	T79	Serous	c.504G>T	p.Met168Ile	Missense	Low
	T79	Serous	c.41G>A	p.Arg14Gln	Missense	Neutral
	T79	Serous	c.1436G>A	p.Arg479Gln	Missense	Medium ∇
	T114	Serous	c.1513C>T	p.Arg505Cys	Missense	Medium ∇
	T162	Serous	c.1436G>A	p.Arg479Gln	Missense	Medium ∇
	T166	Serous	c.1634A>T	p.Tyr545Cys	Missense	Medium
	T167	Serous	c.2065C>T	p.Arg689Trp	Missense	Medium
	T29	Serous	c.1387A>G	p.Thr463Ala	Missense	Medium
	T80	Serous	c.1385C>T	p.Ser462Phe	Missense	Medium
	T80	Serous	c.1322G>C	p.Arg441Pro	Missense	Medium
	T47	Serous	c.1436G>A	p.Arg479Gln	Missense	Medium ∇
	T69	Serous	c.2065C>T	p.Arg689Trp	Missense	Medium
	T32	Clear cell	c.1199_1201delACA	p.del401Asn	In-frame deletion	-
	T77	Clear cell	c.1513C>T	p.Arg505Cys	Missense	Medium ∇
	T84	Endometrioid	c.1268G>T	p.Gly423Val	Missense	Medium
	T85	Endometrioid	c.1436G>A	p.Arg479Gln	Missense	Medium ∇
	T88	Endometrioid	c.994G>T	p.Glu332*	Nonsense	-
	T88	Endometrioid	c.1452G>T	p.Arg484Ser	Missense	High
	T88	Endometrioid	c.1629A>C	p.Arg543Ser	Missense	Low

Gene Name (RefSeq ID; UCSC Transcript Accession ID [^])	Tumor	Histology	Nucleotide Change	Amino Acid Change	Mutation type	Mutation Assessor Predicted Effect on Function
	T94	Endometrioid	c.1393C>T	p.Arg465Cys	Missense	Medium ⁷
	T97	Endometrioid	c.1436G>A	p.Arg479Gln	Missense	Medium ⁷
	T115	Endometrioid	c.1508C>T	p.Ala503Val	Missense	Medium
	T119	Endometrioid	c.1513C>T	p.Arg505Cys	Missense	Medium ⁷
	T178	Mixed	c.1508C>T	p.Ala503Val	Missense	Medium
	T179	Mixed	c.791A>G	p.Gln264Arg	Missense	Medium
	T179	Mixed	c.1972C>T	p.Arg658*	Nonsense	-
<i>SPOP</i> (NM_001007229; uc002ipf.2)	T25	Serous	c.240C>G	p.Ser80Arg	Missense	Medium
	T56	Serous	c.240C>G	p.Ser80Arg	Missense	Medium
	T80	Serous	c.280C>G	p.Pro94Ala	Missense	Low
	T154	Serous	c.362C>A	p.Arg121Gln	Missense	Low
	T110	Clear cell	c.351G>A	p.Met117Ile	Missense	Low
	T153	Clear cell	c.139C>A	p.Glu47Lys	Missense	Medium
<i>MAP3K4</i> (NM_006724; uc003qtn.2)	T79	Serous	c.1837G>A	p.Glu613Lys	Missense	Low
	T79	Serous	c.3928G>T	p.Glu1310*	Nonsense	-
	T80	Serous	c.4165G>A	p.Glu1389Lys	Missense	High
	T65	Serous	c.4077delC	p.Cys1359Alafs*8	Frameshift	-
<i>ABCC9</i> (NM_020297; uc001rfh.2)	T3 (OM1323)	Serous	c.2666G>A	p.Ser889Asn	Missense	Low
	T3 (OM1323)	Serous	c.2868G>T	p.Glu956Asp	Missense	Low
	T70	Serous	c.2185G>T	p.Val729Phe	Missense	Medium
	T75	Serous	c.3381G>A	p.Met1127Ile	Missense	Low
<i>CYP4X1</i> (NM_178033; uc001cqr.1)	T75	Serous	c.1036G>C	p.Val346Leu	Missense	Neutral

Gene Name (RefSeq ID; UCSC Transcript Accession ID [^])	Tumor	Histology	Nucleotide Change	Amino Acid Change	Mutation type	Mutation Assessor Predicted Effect on Function
	T56	Serous	c.211C>A	p.Glu71Lys	Missense	Neutral

[#] Known loss-of-function mutations in *FBXW7*

⁰ Not evaluated by Mutation Assessor

[^] UCSC transcript IDs are based on the hg18 assembly of the human genome sequence

Table 2

Somatic mutations identified in the discovery and prevalence screens of ten chromatin-remodeling genes

Gene Name (RefSeq ID; UCSC Transcript Accession ID ^)	Mutation frequency in serous tumors	Mutation frequency in clear cell tumors	Tumor	Histology	Nucleotide Change	Amino Acid Change	Mutation type	Mutation Assessor Predicted Effect on Function
<i>EP300</i> (NM_001429; uc003azi.3)	8% (4/52)	4% (1/23)	T56	Serous	c.5195G>A	p.Arg1732His	Missense	Medium
			T3 (OMI323)	Serous	c.4879C>T	p.Arg1627Trp	Missense	Medium
			T74	Serous	c.4880G>A	p.Arg1627Gln	Missense	Medium
			T79	Serous	c.4404A>C	p.Lys1468Asn	Missense	Medium
			T113	Clear cell	c.2863C>T	p.Pro955Ser	Missense	Neutral
<i>ARID1A</i> (NM_006015; uc001bmv.1)	6% (3/52)	13% (3/23)	T69	Serous	c.5161C>T	p.Arg1721*	Nonsense	-
			T74	Serous	c.3826C>T	p.Arg1276*	Nonsense	-
			T79	Serous	c.5299G>T	p.Glu1767*	Nonsense	-
			T79	Serous	c.5965C>T	p.Arg1989*	Nonsense	-
			T61	Clear cell	c.1645delC	p.Tyr551Thrfs*68	Frameshift	-
			T82	Clear cell	c.3478_3479insT	p.Leu1160Phefs*33	Frameshift	-
			T113	Clear cell	c.5142G>T	p.Glu1714Asp	Missense	Low
<i>TSPYL2</i> (NM_022117; uc004dtx.1)	6% (3/52)	0% (0/23)	T70	Serous	c.752A>C	p.His251Pro	Missense	-
(NM_022117; uc004drw.2)			T3 (OMI323)	Serous	c.1636G>T	p.Gly546Cys	Missense	Neutral
			T30	Serous	c.1952G>C	p.Gly651Ala	Missense	Neutral
<i>KDM4B</i> (NM_015015; uc002mbq.3)	4% (2/52)	0% (0/23)	T154	Serous	c.2138C>T	p.Pro713Leu	Missense	Neutral
			T3 (OMI323)	Serous	c.964G>A	p.Val322Met	Missense	Low

Gene Name (RefSeq ID; UCSC Transcript Accession ID [^])	Mutation frequency in serous tumors	Mutation frequency in clear cell tumors	Tumor	Histology	Nucleotide Change	Amino Acid Change	Mutation type	Mutation Assessor Predicted Effect on Function
			T3 (OMI1323)	Serous	c.1855C>T	p.Pro619Ser	Missense	Low
<i>TRPM16</i> (NM_006470; uc002g0x.2)	2% (1/52)	0% (0/23)	T80	Serous	c.1319delC	p.Tyr440Metfs*3	Frameshift	-
<i>CTCF</i> (NM_006565; uc002et1.2)	2% (1/52)	0% (0/23)	T70	Serous	c.1094A>C	p.Lys365Thr	Missense	Neutral
<i>HDAC7</i> (NM_015401; uc001rqi.2)	2% (1/52)	0% (0/23)	T75	Serous	c.1024G>A	p.Glu342Lys	Missense	Low
<i>TRRAP</i> (NM_003496; uc003upp.1)	2% (1/52)	0% (0/23)	T47	Serous	c.5035G>A	p.Ala1679Thr	Missense	Low
<i>YEATS4</i> (NM_006530; uc001sux.1)	2% (1/52)	0% (0/23)	T27	Serous	c.617delA	p.Thr206Leufs*1	Frameshift	-
<i>BAZ1B</i> (NM_032408; uc003tyc.1)	4% (2/52)	4% (1/23)	T65	Serous	c.136A>C	p.Ser46Arg	Missense	Low
			T3 (OMI1323)	Serous	c.3448G>A	p.Glu1150Lys	Missense	Neutral
			T77	Clear cell	c.3167G>A	p.Arg1056His	Missense	Low

⁰Not evaluated by Mutation Assessor

[^]UCSC transcript IDs are based on the hg18 assembly of the human genome sequence